UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares.

Her expertise is in personal finance and investing, and real estate. Investopedia / Michela Buttignol The Wilcoxon test is a nonparametric statistical hypothesis test that compares two paired ...